This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Ischemia/ reperfusion injury	TNNI3 interacting kinase (TNNI3K)	<p>Patient tissue sample and rodent studies suggest inhibiting TNNI3K could help treat cardiac reperfusion injury. In human tissues, TNNI3K was expressed specifically in cardiomyocytes, and its expression was higher in patients with ischemic cardiomyopathy than in healthy individuals. In ischemic mice, small molecule inhibitors of Tnni3k decreased infarct size compared with vehicle. In a mouse model of extended ischemia, intraperitoneal injection of a Tnni3k inhibitor at reperfusion and six hours after reperfusion decreased cardiac dysfunction and fibrosis compared with vehicle injection. Next steps include testing the compounds in a canine model of cardiac dysfunction.</p> <p>GlaxoSmithKline plc collaborated on and has filed for a patent covering the composition of TNNI3K inhibitors.</p> <p>SciBX 6(44); doi:10.1038/scibx.2013.1255 Published online Nov. 14, 2013</p>	Patent application filed; licensing status undisclosed	<p>Vagnozzi, R.J. <i>et al. Sci. Transl. Med.</i>; published online Oct. 16, 2013; doi:10.1126/scitranslmed.3006479</p> <p>Contact: Thomas Force, Temple University School of Medicine, Philadelphia, Pa. e-mail: thomas.force@temple.edu</p>